Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $69.6 million.

  • Corcept Therapeutics' Receivables - Net rose 1659.83% to $69.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.6 million, marking a year-over-year increase of 1659.83%. This contributed to the annual value of $54.0 million for FY2024, which is 3125.5% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Receivables - Net stood at $69.6 million, which was up 1659.83% from $64.6 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Receivables - Net registered a high of $69.6 million during Q3 2025, and its lowest value of $22.2 million during Q1 2021.
  • Its 5-year average for Receivables - Net is $41.4 million, with a median of $32.6 million in 2023.
  • As far as peak fluctuations go, Corcept Therapeutics' Receivables - Net crashed by 1680.41% in 2021, and later surged by 8895.48% in 2024.
  • Over the past 5 years, Corcept Therapeutics' Receivables - Net (Quarter) stood at $27.6 million in 2021, then increased by 12.42% to $31.1 million in 2022, then soared by 32.41% to $41.1 million in 2023, then soared by 31.26% to $54.0 million in 2024, then rose by 29.0% to $69.6 million in 2025.
  • Its Receivables - Net stands at $69.6 million for Q3 2025, versus $64.6 million for Q2 2025 and $61.8 million for Q1 2025.